Medical Device News Magazine

Praxis Medical Announces FDA Clearance of the EndoCore EBUS-TBNA Biopsy Device

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Praxis Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the EndoCore EBUS-TBNA fine needle biopsy device.

Endobronchial ultrasound with transbronchial needle aspiration ( EBUS-TBNA ) is used for the diagnosis and staging of lung cancer. This procedure is performed by inserting a long, flexible fine needle through a bronchoscope for biopsy and pathological analysis. The cellular material collected can be viewed under a microscope to determine if a mass is malignant and identify tumor-specific mutations to guide treatment.

The EndoCore is a novel device designed to enhance the outcomes of this procedure. The device is powered by a motor that rotates the needle during biopsy to facilitate cellular harvesting. This unique rotary motion enables the needle to shear off large tissue samples that can help physicians make a comprehensive diagnosis.

“We are excited by the implications of how this device could progress the standard of care. Improving EBUS-TBNA sensitivity, diagnostic yield, and ancillary testing capabilities would allow for an expedited workup of all types of adenopathy while maintaining procedural efficiency and low complication rates,” said Dr. Joseph Romero, a Pulmonologist at Morton Plant Hospital in Clearwater, FL. “We expect the EndoCore device will collect larger samples of tissue with higher cellularity which could translate to higher success rates for ancillary testing. This will be particularly important for rarer tumors, metastatic disease, lymphoma, and benign diseases such as sarcoidosis where traditional EBUS-TBNA has a lower yield.”

The EndoCore builds upon Praxis’ existing product portfolio which includes the CytoCore, a motorized percutaneous fine needle biopsy device that received FDA clearance in March 2020. Together these products show promise to revolutionize the way fine needle biopsies are being performed and continue Praxis’ mission to improve the lives of patients through advancements in technology.

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.